New hope for Drug-Resistant stomach cancer? sorafenib trial underway
NCT ID NCT00265798
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug sorafenib in 38 patients with gastrointestinal stromal tumor (GIST) that has worsened despite treatment with imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumors grow and by cutting off blood supply to the cancer. The study measures how many patients see their tumors shrink and how long the disease stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sorafenib (Nexavar)
What this could lead to
If it works, sorafenib could offer a new treatment option for patients with GIST that no longer responds to standard therapies.
What could go wrong
This is a small, early-phase trial (38 participants) and may not lead to a widely available treatment. The drug may cause side effects and may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62702, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Decatur Memorial Hospital
Decatur, Illinois, 62526, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States